Melanoma-associated antigen C1 (1083-1091)

Melanoma-associated antigen C1 (1083-1091) is a synthetic peptide fragment derived from the MAGE-C1 protein, a member of the melanoma-associated antigen gene family. Characterized by its defined amino acid sequence, this peptide represents a precise epitope within the larger MAGE-C1 protein, which is known for its restricted expression in various tumor types, particularly melanoma, and limited presence in normal tissues. The unique sequence and immunological relevance of this peptide make it a valuable tool for exploring antigen-specific responses, T-cell recognition, and tumor immunology in a controlled research setting. Its well-characterized structure and biological significance have established it as an essential reagent in studies seeking to understand the molecular mechanisms underlying tumor-associated antigenicity and immune surveillance.

Epitope mapping: As a defined peptide epitope, the fragment is widely employed in epitope mapping studies to delineate the specific regions of MAGE-C1 recognized by cytotoxic T lymphocytes (CTLs) or other immune effectors. By incorporating this peptide into assays such as ELISPOT or intracellular cytokine staining, researchers can accurately identify T-cell populations that respond to the MAGE-C1 antigen, thereby advancing the understanding of immune recognition patterns in cancer immunology.

Immunogenicity assessment: The peptide serves as a crucial reagent in evaluating the immunogenic potential of MAGE-C1-derived sequences in preclinical models. By exposing immune cells to this defined fragment, investigators can assess the magnitude and specificity of immune responses, including the activation and proliferation of antigen-specific T cells. Such studies are instrumental in characterizing the determinants of effective anti-tumor immunity and guiding the rational design of immunotherapeutic strategies.

Peptide-MHC binding analysis: In the context of major histocompatibility complex (MHC) research, the peptide is utilized to study the binding affinity and stability of peptide-MHC complexes. By synthesizing this fragment and analyzing its interaction with specific HLA alleles, scientists can elucidate the molecular determinants of antigen presentation, which is fundamental to understanding how tumor-associated antigens are displayed to the immune system and how immune escape mechanisms may arise.

Assay development: The defined sequence and immunological relevance of the peptide make it a preferred standard for the development and validation of immune monitoring assays. It is frequently incorporated into protocols for functional assays, such as cytotoxicity or proliferation assays, to benchmark the performance of immune cells or to calibrate assay sensitivity and specificity. This facilitates reliable detection of antigen-specific responses in experimental and translational research settings.

Cancer immunology research: The peptide's role as a representative epitope of the MAGE-C1 antigen positions it as a critical tool in broader cancer immunology investigations. By providing a model system for studying tumor antigen processing, presentation, and immune recognition, it enables researchers to dissect the mechanisms by which tumors evade immune detection and to explore strategies for enhancing anti-tumor immunity. Its application supports the advancement of knowledge in tumor antigenicity, immune escape, and the development of novel immunotherapeutic approaches.

1. Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics

2. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment

3. Urinary Metabolites Associated with Blood Pressure on a Low-or High-Sodium Die

4. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy

5. Extended exenatide administration enhances lipid metabolism and exacerbates pancreatic injury in mice on a high fat, high carbohydrate diet